All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-YC1093 | Human anti-SLC30A8 T cell receptor (TC4), pCDTCR1 | Human | TC4 | Human | LLIDLTSFLL | HLA-A*02:01 | Lentiviral vector | |
TCR-YC1094 | Human anti-SLC30A8 T cell receptor (TD5), pCDTCR1 | Human | TD5 | Human | VVTGVLVYL | HLA-A*02:01 | Lentiviral vector | |
TCR-YC1095 | Human anti-SLC30A8 T cell receptor (TF4), pCDTCR1 | Human | TF4 | Human | VVTGVLVYL | HLA-A*02:01 | Lentiviral vector | |
TCR-YC1096 | Human anti-SLC30A8 T cell receptor (TF5), pCDTCR1 | Human | TF5 | Human | VVTGVLVYL | HLA-A*02:01 | Lentiviral vector | |
TCR-YC1097 | Human anti-SLC30A8 T cell receptor (UA5), pCDTCR1 | Human | UA5 | Human | VVTGVLVYL | HLA-A*02:01 | Lentiviral vector | |
TCR-YC1098 | Human anti-SLC30A8 T cell receptor (UC5), pCDTCR1 | Human | UC5 | Human | VMIIVSSLAV | HLA-A*02:01 | Lentiviral vector | |
TCR-YC1099 | Human anti-SLC30A8 T cell receptor (UD5), pCDTCR1 | Human | UD5 | Human | LLSLFSLWL | HLA-A*02:01 | Lentiviral vector | |
TCR-YC1100 | Human anti-SLC30A8 T cell receptor (UF5), pCDTCR1 | Human | UF5 | Human | LLSLFSLWL | HLA-A*02:01 | Lentiviral vector | |
TCR-YC1101 | Human anti-SLC30A8 T cell receptor (UH4), pCDTCR1 | Human | UH4 | Human | VVTGVLVYL | HLA-A*02:01 | Lentiviral vector | |
TCR-YC1102 | Human anti-SLC30A8 T cell receptor (VH4), pCDTCR1 | Human | VH4 | Human | LLSLFSLWL | HLA-A*02:01 | Lentiviral vector | |
TCR-YC1103 | Human anti-SLC30A8 T cell receptor (WC6), pCDTCR1 | Human | WC6 | Human | LLSLFSLWL | HLA-A*02:01 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION